Insulin efsitora alfa is a novel insulin analog developed by Eli Lilly for the treatment of diabetes. Its glycemic control and safety were found similar to insulin degludec in a phase II trial. From Wikipedia
Late-stage studies show efsitora achieves comparable blood sugar control, offering a potential shift in diabetes treatment.
